← Giancarlo Viberti

Papers by Giancarlo Viberti

Page 1 · newest first

1. Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysisEuropean Heart Journal · 2025
2. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysisThe Lancet · 2021
3. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisThe Lancet · 2021
4. Systemic Inflammation Precedes Microalbuminuria in DiabetesSHILAP Revista de lepidopterología · 2019
5. Predictors for the development of microalbuminuria and interaction with renal functionJournal of Hypertension · 2017
6. A pragmatic lifestyle modification programme reduces the incidence of predictors of cardio-metabolic disease and dysglycaemia in a young healthy urban South Asian population: a randomised controlled trialBMC Medicine · 2017
7. Increased Arterial Stiffness is an Independent Predictor of Renal Function Decline in Patients With Type 2 Diabetes Mellitus Younger Than 60 YearsJournal of the American Heart Association · 2017
8. The effect of dietary changes on distinct components of the metabolic syndrome in a young Sri Lankan population at high risk of CVDBritish Journal Of Nutrition · 2016
9. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized studyBMC Nephrology · 2014
10. The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic NephropathyJournal of the American Society of Nephrology · 2014
11. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow‐Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study DiscontinuationJournal of the American Heart Association · 2014
12. Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor AntagonistClinical Journal of the American Society of Nephrology · 2014
13. Effect of Renin-Angiotensin System Blockade on Soluble Klotho in Patients with Type 2 Diabetes, Systolic Hypertension, and AlbuminuriaClinical Journal of the American Society of Nephrology · 2013
14. Effect of Spironolactone and Amiloride on Thiazolidinedione-Induced Fluid Retention in South Indian Patients with Type 2 DiabetesClinical Journal of the American Society of Nephrology · 2012
15. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 DiabetesSurvey of Anesthesiology · 2012
16. Prevention of microalbuminuria in patients with type 2 diabetes and hypertensionJournal of Hypertension · 2012
17. Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide MonotherapyClinical Journal of the American Society of Nephrology · 2011
18. Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPTDiabetes · 2011
19. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 DiabetesNew England Journal of Medicine · 2011
20. Proteinuria in DiabetesJournal of the American Society of Nephrology · 2010
21. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trialsDiabetologia · 2010
22. Avosentan for Overt Diabetic NephropathyJournal of the American Society of Nephrology · 2010
23. Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Prevents Albuminuria but Not Glomerulosclerosis in Experimental DiabetesAmerican Journal of Nephrology · 2010
24. Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuriaJournal of Hypertension · 2009
25. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism · 2009
26. Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight GainDiabetes Care · 2009
27. Mechanical forces and TGF 1 reduce podocyte adhesion through  3 1 integrin downregulationNephrology Dialysis Transplantation · 2009
28. Renal Functional Response to Protein Loading in Type 1 (Insulin-Dependent) Diabetic Patients on Normal or High Salt Intake˜The œNephron journals/Nephron journals · 2008
29. Dietary Composition and Renal Function in Healthy Subjects˜The œNephron journals/Nephron journals · 2008
30. Threshold Effect of Plasma Glucose in the Glomerular Hyperfiltration of Diabetes˜The œNephron journals/Nephron journals · 2008
31. Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic MiceDiabetes · 2008
32. Rosiglitazone-Associated Fractures in Type 2 DiabetesDiabetes Care · 2008
33. Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure LoweringHypertension · 2008
34. HDL Composition Predicts New-Onset Cardiovascular Disease in Patients With Type 1 DiabetesDiabetes Care · 2007
35. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitusJournal of Hypertension · 2007
36. Mechanical Forces in Diabetic Kidney DiseaseJournal of the American Society of Nephrology · 2007
37. Podocyte-Specific Expression of Angiopoietin-2 Causes Proteinuria and Apoptosis of Glomerular EndotheliaJournal of the American Society of Nephrology · 2007
38. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non‐diabetic patientsDiabetes Obesity and Metabolism · 2007
39. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine · 2006
40. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and EuropeDiabetic Medicine · 2006
41. Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid RetentionJournal of the American Society of Nephrology · 2006
42. The link between mechanical stretch and glucose metabolism--a conceptual advance in understanding diabetic (and non diabetic?) renal diseaseNephrology Dialysis Transplantation · 2006
43. Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 DiabetesDiabetes · 2006
44. Serum Lipids and the Progression of Nephropathy in Type 1 DiabetesDiabetes Care · 2006
45. Aortic Pulse Wave Velocity and Albuminuria in Patients with Type 2 DiabetesJournal of the American Society of Nephrology · 2005
46. Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal DiseaseJournal of the American Society of Nephrology · 2005
47. Mechanical Stretch Induces Monocyte Chemoattractant Activity via an NF-κB-Dependent Monocyte Chemoattractant Protein-1-Mediated Pathway in Human Mesangial CellsJournal of the American Society of Nephrology · 2005
48. Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patientsNephrology Dialysis Transplantation · 2004
49. Sex Differences in Age-Related Stiffening of the Aorta in Subjects With Type 2 DiabetesHypertension · 2004
50. Effect of Low-Dose Perindopril/Indapamide on Albuminuria in DiabetesHypertension · 2003